cardiovascular disease modeling – Science

Mini Blood Vessels in a Miniature Plate: 96-Well Platform Streamlines Organoid Production

Gregory Coleman — Sun, 04 Oct 2026 18:19:48 +0000

Blood vessel organoids, tiny three-dimensional clusters of human cells that recapitulate the architecture of living vasculature, have quickly become one of the most valuable tools in cardiovascular research. Now a team at the First Affiliated Hospital of Bengbu Medical University in China has reengineered how these organoids are made, moving the entire production process into a standard 96-well plate. The work, published as an open-access article in Cellular and Molecular Life Sciences, describes a scalable platform that grows one blood vessel organoid per well, allowing dozens of independent cultures to be generated, treated, and analyzed in parallel on a single plastic plate that fits in the palm of a hand.

Cardiovascular disease remains the leading cause of death worldwide, and much of that mortality traces back to vascular dysfunction, the failure of blood vessels to develop properly or to respond correctly to physiological stress. Understanding why vessels fail requires experimental models that capture the complexity of human vascular tissue, something that two-dimensional cell monolayers have never managed to do convincingly. Blood vessel organoids derived from human pluripotent stem cells address this gap by self-organizing into three-dimensional structures containing the key cellular constituents of vessel walls, providing researchers with a living miniature of human vasculature that can be studied in a dish.

The original differentiation framework that made such organoids possible was established by Wimmer and colleagues, whose protocol guided human pluripotent stem cells through a carefully choreographed sequence of developmental signals so that they matured into vascular tissue. That pioneering method, however, was built around bulk cultures in which large numbers of cell aggregates developed together in shared vessels. In such crowded conditions, neighboring cell spheres readily fuse with one another, and researchers must later perform laborious dissection to separate individual organoids. The fusion problem also means that aggregates cannot be tracked as independent experimental units, which limits the design of experiments that require many distinct conditions to be compared side by side.

The Bengbu team, led by Zhuxin Zhou, Benchi Feng, and senior authors Yong Gao and Shiyuan Chen, adapted the established differentiation framework to a U-bottom 96-well ultra-low-attachment plate. The key design choice is elegant in its simplicity: an equal number of human pluripotent stem cells is seeded into each individual well, and each well then gives rise to exactly one cell aggregate that differentiates into one blood vessel organoid. Because the U-shaped bottom of each well concentrates the cells at its center while the ultra-low-attachment surface prevents them from sticking to the plastic, the developing aggregate sits in its own private microenvironment. The one-aggregate-per-well configuration physically prevents fusion between neighboring aggregates, since each aggregate is confined to a separate well from the very start of differentiation.

This physical isolation has consequences that go far beyond convenience. Each blood vessel organoid can be cultured, treated, sampled, collected, and analyzed completely independently of its neighbors. A researcher can expose one well to a drug candidate, another to a different dose, and a third to a control vehicle, all while every organoid remains an intact, individually traceable unit. Different wells on the same plate can be assigned to distinct cell lines, treatment groups, doses, culture conditions, or time points, and the number of wells actually occupied can be adjusted freely to match the scale of any given experiment. A pilot study might use a single row of eight wells, while a full screening campaign could fill the entire plate with ninety-six independently manipulated organoids.

To demonstrate that the platform produces genuine vascular tissue, the researchers generated blood vessel organoids from two different sources of human pluripotent stem cells: the widely used H9 embryonic stem cell line and induced pluripotent stem cells, which are adult cells reprogrammed back into an embryonic-like state. They then assessed whether the resulting organoids expressed and correctly organized the molecular hallmarks of blood vessel tissue. Two complementary techniques anchored this quality control. Reverse transcription quantitative polymerase chain reaction, or RT-qPCR, measured the levels of messenger RNA for vascular marker genes, revealing which cell-type-specific genetic programs had been activated during differentiation. Immunofluorescence staining, in turn, visualized where the corresponding proteins accumulated within the organoids, confirming that vascular cells were not merely present but properly organized into vessel-like structures.

The practical advantages of the 96-well format extend to cost and labor, two factors that often determine whether an organoid method spreads through the research community. Conventional organoid protocols consume substantial quantities of expensive reagents and consumables, including type I collagen and Matrigel, the extracellular matrix mixtures used to support three-dimensional growth. Because each well in the new platform requires only the material needed for a single organoid, the total consumption of these costly components drops considerably, making the method more cost-effective for laboratories with limited budgets. The platform also eliminates much of the repetitive handling that burdens traditional workflows. The authors specifically highlight the reduction in rehanging operations, the manual transfers used to keep developing aggregates properly suspended, and the subsequent dissection work needed to separate fused organoids, saving both time and physical effort at the bench.

Flexibility is another defining feature of the system. Because plate occupancy is adjustable, the number of organoids generated can be tuned precisely to the requirements of each experiment rather than dictated by the protocol. A laboratory studying a rare patient-derived induced pluripotent stem cell line might need only a handful of organoids for a characterization study, while a pharmacology group testing a panel of vascular drugs might need hundreds across multiple plates. The platform accommodates both extremes on the same standardized hardware, which means results from different laboratories using the system should be more directly comparable than results from bespoke, hand-built organoid setups.

The researchers position the platform as a foundation for future compound-testing applications, and the logic is straightforward. Drug screening in cardiovascular research has long suffered from a shortage of human-relevant three-dimensional models that can be produced at sufficient scale and consistency. A 96-well plate is the native format of automated liquid handlers, plate readers, and high-content imaging systems, so organoids grown in this configuration slot directly into existing laboratory automation infrastructure. Multiplexed experiments, in which many compounds, doses, and genetic backgrounds are tested simultaneously, become a realistic prospect rather than an aspiration, and the ability to run distinct cell lines on a single plate opens the door to direct comparisons between healthy and disease-derived vascular tissue under identical conditions.

The work arrives at a moment when organoid technology is maturing from a specialist curiosity into a mainstream platform for disease modeling and drug development, and it addresses one of the field’s most persistent bottlenecks: throughput. By preserving the biological logic of the established differentiation framework while redesigning its physical container, the Bengbu team has created a bridge between the qualitative richness of blood vessel organoids and the quantitative demands of modern biomedical research. The study received support from the Research Fund for the Construction and Transformation of Vascular Organoid of The First Affiliated Hospital of Bengbu Medical University and from the Key Project of Natural Science Research in Universities of Anhui Province, and the article is published open access under a Creative Commons license. For laboratories worldwide that have hesitated to adopt vascular organoids because of cost, labor, or scalability concerns, the message of this platform is that the barrier to entry may now be no higher than a standard cell culture plate.

Subject of Research: A 96-well ultra-low-attachment platform for constructing human pluripotent stem cell-derived blood vessel organoids

Article Title: A 96-well platform for blood vessel organoid construction

Article References: Zhou, Z., Feng, B., Cheng, X., Zhang, X., Yu, C., Gao, Y., & Chen, S. (2026). A 96-well platform for blood vessel organoid construction. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06388-7

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06388-7

Keywords: blood vessel organoids, human pluripotent stem cells, 96-well plate, ultra-low-attachment, vascular differentiation, cardiovascular disease modeling, high-throughput screening, organoid platform, embryonic stem cells, induced pluripotent stem cells, multiplexed testing, three-dimensional culture

New Artery-on-a-Chip Technologies Advance Construction Strategies and Disease Modeling

Nathaniel Bowman — Fri, 28 Aug 2026 20:22:28 +0000

Cardiovascular disease remains the world’s leading cause of death, and the arteries—dynamic tubes that constantly bend, stretch, pulse and respond to flowing blood—are where many of its most dangerous forms begin. A new review argues that a technology small enough to fit on a microscope slide could help researchers study these diseases with a realism that conventional laboratory models often cannot provide. Known as the artery-on-a-chip, the platform combines microfluidics, tissue engineering and biomaterials to recreate sections of human arteries in controlled laboratory devices. The review, published in Angiogenesis, surveys how these systems are built and how they are being adapted to investigate thrombosis, atherosclerosis, pulmonary hypertension and aneurysms. Its central message is that the future of vascular research may depend on reproducing not only the cells lining an artery, but also the physical forces that shape their behaviour.

For decades, researchers have relied heavily on animal models and two-dimensional cell cultures to investigate arterial disease and test potential medicines. Both approaches have provided essential biological insights, but each captures only part of the environment inside a living artery. Flat cultures usually grow cells on rigid plastic, eliminating the three-dimensional architecture of the vessel wall and exposing cells to an artificial mechanical setting. Animals, meanwhile, can reproduce complex physiology but differ from humans in anatomy, immune responses, metabolism and disease progression. These differences can make a treatment appear promising before clinical testing, only for its effects to be weaker—or absent—in people. Artery-on-a-chip systems are designed to occupy the space between these extremes by offering human cells in a structured, perfused and mechanically active microenvironment that can be observed and manipulated in real time.

At its simplest, an artery-on-a-chip contains a microscopic channel through which a liquid is pumped, mimicking blood flow, alongside or within a compartment containing vascular cells and a supporting matrix. More sophisticated devices reproduce the layered structure of an arterial wall. Endothelial cells form the inner lining, vascular smooth-muscle cells provide contractile support in the media, and additional stromal or connective-tissue components can help model the outer vessel environment. The channel may be circular rather than rectangular, allowing researchers to approximate the geometry of a natural artery. Flexible materials can permit the channel to expand and contract as pressure changes, while membranes or hydrogel layers can separate cell populations without preventing biochemical communication. Some designs use three-dimensional printing or bioprinting to create bends, branches, stenoses and patient-specific geometries that would be difficult to reproduce in ordinary culture dishes.

The review emphasizes that biological fidelity depends on a carefully balanced set of design parameters. The extracellular matrix, the network of proteins surrounding cells, provides both biochemical signals and mechanical resistance. Collagen, elastin-like materials, gelatin-based hydrogels and engineered biomaterials can be tuned to reproduce different levels of stiffness and elasticity. This matters because arterial cells sense their surroundings through mechanotransduction: molecular systems convert physical inputs into changes in gene expression, cytoskeletal organization and cell function. Endothelial cells also respond to wall shear stress, the frictional force produced by flowing fluid along the vessel surface. Under steady, directional flow, they tend to elongate and align with the direction of movement. Disturbed or oscillating flow can trigger inflammatory signalling, weaken barrier function and promote the cellular changes associated with atherosclerosis. A chip that controls flow therefore becomes a way to expose cells to specific mechanical conditions rather than merely keeping them alive.

Pressure and cyclic stretch add another layer of realism. Arteries do not experience a constant diameter: each heartbeat sends a pressure wave through the vessel, repeatedly deforming the wall. Researchers can reproduce this behaviour by applying pneumatic pressure, deforming flexible chambers or controlling the compliance of the surrounding material. Cyclic strain influences vascular smooth-muscle cells, which can shift between contractile, proliferative, synthetic and inflammatory states. These phenotypic changes are important in arterial stiffening, plaque development and aneurysm formation. Matrix stiffness is equally consequential. A rigid environment can alter the response of endothelial cells to shear stress and may interfere with normal mechanosensing. By independently adjusting stiffness, stretch, pressure and flow, artery-on-a-chip experiments can dissect how physical factors interact—something that is difficult to achieve in a living animal or a standard two-dimensional culture.

One of the most immediate applications is the study of arterial thrombosis, in which platelets and blood-clotting proteins accumulate to obstruct blood flow. A chip can incorporate narrowed regions, damaged or activated endothelium and controlled pulses of whole blood, allowing investigators to observe platelet adhesion, activation and aggregation under defined shear conditions. The geometry is critical: blood moving through a stenosis accelerates, separates and forms complex flow patterns downstream. These local changes can influence how von Willebrand factor unfolds, how platelets attach and how a fragile deposit develops into a more stable thrombus. Researchers can then introduce antiplatelet or anticoagulant drugs and measure how effectively they prevent or dissolve clot formation. Because the device can be imaged continuously, it may reveal the difference between a treatment that reduces platelet attachment and one that merely slows the later growth of an established clot. The review also highlights the growing use of three-dimensional printing and anatomically accurate geometries, including patient-specific arterial shapes, to make thrombosis models more clinically relevant.

Atherosclerosis presents a broader challenge because it develops through a long interaction among endothelial dysfunction, lipids, immune cells, smooth-muscle cells and the extracellular matrix. Artery-on-a-chip models can recreate some of these interactions under flow, including the disturbed haemodynamics found near branches, curves and narrowed segments. Researchers may perfuse blood or selected immune-cell populations through a channel lined with endothelial cells, then examine how monocytes attach, migrate into the vessel wall and contribute to inflammation. In multilayer systems, smooth-muscle cells can move beneath the endothelium, while fluorescent particles or lipoproteins are tracked as they cross the endothelial barrier. Single-cell analysis and high-resolution imaging can add molecular detail, identifying shifts in cell state that are hidden when all cells are averaged together. Such platforms could also help test therapies aimed at vascular inflammation, plaque stability or atherothrombosis, while reducing dependence on animal models whose plaque biology does not always match that of humans.

The technology is being extended beyond atherosclerosis and clotting. Pulmonary hypertension, a disease marked by abnormal remodelling and increased resistance in the pulmonary arteries, can be modelled by combining endothelial cells, smooth-muscle cells and disease-relevant mechanical conditions. The review describes how such systems may help investigate signalling pathways linked to endothelial dysfunction and smooth-muscle proliferation, including pathways involving BMPR2 and SOX17. Aneurysm models focus on the progressive weakening and expansion of the arterial wall. By tuning wall stiffness, cyclic stretch and cellular composition, researchers can study how smooth-muscle cells lose their contractile identity, how matrix-degrading processes reshape the vessel and how abnormal flow concentrates mechanical stress. Patient-derived cells and induced pluripotent stem-cell-derived vascular cells offer a route toward models that reflect individual genetic or disease characteristics. In principle, a patient-specific artery-on-a-chip could allow a medicine to be assessed against the biology of a particular person rather than an average laboratory vessel.

Despite the excitement, the review makes clear that artery-on-a-chip systems are not yet a universal replacement for animals or clinical studies. Long-term culture remains difficult: cells may lose their specialised identity, membranes can deteriorate, hydrogels can remodel and microfluidic channels can clog or absorb small drug molecules. Polydimethylsiloxane, a widely used chip material, is flexible and easy to manufacture, but its tendency to absorb hydrophobic compounds can distort pharmacological measurements. Devices also differ widely in channel dimensions, materials, cell sources, flow rates and reporting standards, making results difficult to compare across laboratories. Real arteries contain multiple interacting cell types, circulating blood components, nerves, immune signals and organ-level influences that a single chip may not capture. The researchers therefore call for greater standardization, improved long-term stability and models capable of coupling several disease factors at once. They envision future systems that integrate patient-derived cells, realistic anatomy, programmable haemodynamics, advanced imaging and automated analysis. If those challenges can be overcome, the artery-on-a-chip could become more than a miniature vessel: it could serve as a dynamic testing ground for discovering why arteries fail, predicting which treatments will work and bringing vascular therapies closer to the biology of real patients.

Angiogenesis, 29, Article 17. https://doi.org/10.1007/s10456-026-10030-2>

Subject of Research: Cancer

Article Title: New Artery-on-a-Chip Technologies Advance Construction Strategies and Disease Modeling

Article References: Chang, S.-Q., Qiao, L., Abodunrin, O. D., Zou, L., & Huang, N.-P. (2026). Advanced technologies of artery-on-a-chip: a review of construction strategies and disease models. Angiogenesis, 29(2), Article 17. https://doi.org/10.1007/s10456-026-10030-2

Image Credits: AI Generated

DOI: 10.1007/s10456-026-10030-2

Keywords: 3D artery tissue recreation, advances in vascular tissue engineering, aneurysm simulation on chip, artery-on-a-chip, biomaterials for artery-on-a-chip, cardiovascular disease modeling, lab-on-a-chip artery models, microfluidics in vascular research, physical forces in artery disease studies, pulmonary hypertension research tools, thrombosis and atherosclerosis in microfluidic devices, tissue engineering for artery modeling

Self-Assembled Cardiac Organoids Model Heart Chambers

Ophelia Keating — Tue, 02 Jun 2026 20:56:27 +0000

In a groundbreaking leap for cardiovascular research, scientists have engineered self-assembled chamber-like cardiac organoids that faithfully mimic the complex architecture and functionality of human heart chambers. This pioneering development not only provides a transformative model for studying cardiac chamber formation but also establishes a robust platform for assessing drug-induced cardiotoxicity, potentially revolutionizing how new therapeutics are evaluated before clinical trials. Published this year in Nature Communications, the work by Zou, Wang, Zheng, and colleagues spotlights the convergence of stem cell biology, tissue engineering, and regenerative medicine, presenting an unprecedented window into the earliest steps of heart development and disease modeling.

The human heart’s intricate structure—comprising multiple chambers each with specialized functions—is notoriously challenging to replicate in vitro. Traditional two-dimensional cardiomyocyte cultures lack the spatial organization and mechanical cues necessary for proper cardiac maturation. While previous three-dimensional cardiac organoids have demonstrated contractile activity and cell heterogeneity, recreating chamber-like structures that resemble true heart morphology has remained elusive. Zou et al. surmount this hurdle by harnessing self-assembly principles, enabling pluripotent stem cells to organize autonomously into defined, chambered organoids. This architectural mimicry is essential, as the heart’s ability to pump blood relies heavily on the precise formation and interplay of distinct chambers.

Central to their approach is the optimization of culture conditions that guide stem cells down specific differentiation trajectories while promoting cellular interactions and biomechanical feedback mechanisms. Through a carefully orchestrated protocol, the research team modulated signaling pathways such as Wnt, BMP, and Notch, which are pivotal during embryonic heart development. This biochemical guidance, combined with tailored extracellular matrix components, facilitated the aggregation of cardiomyocytes, cardiac fibroblasts, and endothelial cells into a cohesive, hollow structure reminiscent of heart chambers. Notably, the organoids exhibited spontaneous contractions with coordinated electrical conduction, underscoring their functional maturity.

This model opens unprecedented avenues for interrogating the molecular and biomechanical determinants of cardiac chamber morphogenesis. Researchers can now probe how gradients of morphogens and mechanical forces sculpt chamber identity, valve formation, and myocardial patterning in a controlled laboratory environment. By recapitulating key developmental milestones in vitro, these organoids provide insight into congenital heart defects and allow for the dissection of complex gene-environment interactions that underlie cardiac malformations. The study paves the way for elucidating pathway-specific perturbations linked to heart disease.

In addition to developmental insights, the chamber-like organoids serve as a sophisticated platform for pharmacological screening. Drug-induced cardiotoxicity remains a pervasive challenge in drug development, often causing late-stage failures or post-market withdrawals. Current preclinical models, including animal testing and 2D cultures, only partially recapitulate human cardiac physiology, limiting predictive accuracy. These self-assembled cardiac organoids, by contrast, provide a human-relevant context to assess the electrophysiological, structural, and contractile effects of novel compounds, capturing subtle toxicities that conventional assays might overlook.

The research team demonstrated the utility of their platform by testing well-known cardiotoxic agents, revealing dose-dependent disruptions in organoid rhythm and contractile force. Their findings correlated with clinical manifestations observed in patients, suggesting that this model can forecast adverse cardiac responses with enhanced fidelity. This capability could streamline drug safety assessments, reduce reliance on animal models, and ultimately expedite the delivery of safer cardiovascular therapeutics to patients.

Crucially, the organoids produced by Zou et al. display remarkable reproducibility and scalability, addressing long-standing challenges in organoid research. By standardizing the self-assembly process, the team ensured consistent formation of chambers exhibiting uniform size, morphology, and cell composition across batches. This consistency lays the groundwork for larger-scale applications such as high-throughput drug screening and precision medicine initiatives, where patient-derived organoids could be tested against personalized therapeutic regimens.

Furthermore, the researchers leveraged advanced imaging and electrophysiological techniques to characterize organoid dynamics in real time. Using high-resolution confocal microscopy and multi-electrode arrays, they mapped calcium transients, electrical propagation, and mechanical contraction patterns within the chamber-like structures. These comprehensive analyses confirmed that the organoids not only structurally resemble heart chambers but also functionally emulate their synchronous beating and electrical coupling, hallmarks of a physiologically relevant cardiac model.

Beyond drug testing, the potential of these cardiac organoids extends into regenerative medicine. The ability to self-organize into chambered constructs suggests their suitability for bioengineered tissue grafts aimed at repairing damaged myocardium. Although clinical translation remains distant, the mechanistic insights gained from these models can inform strategies for enhancing cardiac regeneration, integrating stem cell therapies, and engineering next-generation heart patches.

Zou and colleagues also touched upon the ethical and logistical advantages of their organoid system. By reducing dependence on animal experimentation, their model aligns with the principles of the 3Rs (replacement, reduction, refinement) in biomedical research. Additionally, the use of human induced pluripotent stem cells enables studies on genetically diverse populations, enhancing our understanding of how individual genetic backgrounds influence heart development and drug responses.

The combination of bioengineering, developmental biology, and pharmacology embodied in this research illustrates a paradigm shift in cardiovascular science. Where once the heart was an impenetrable black box, the creation of chamber-like cardiac organoids offers a tangible window into its formation, function, and pathologies. This synthetic heart tissue platform promises to accelerate the discovery of novel treatments for heart disease, a leading cause of mortality worldwide, with profound implications for public health.

Looking forward, the research sets the stage for integrating other cell types critical to heart function, such as immune cells and specialized conduction system components, to achieve even more physiologically comprehensive organoids. Advances in microfluidics and tissue perfusion could further enhance nutrient delivery and waste removal, mimicking in vivo conditions and prolonging organoid survival. Such innovations will push the boundaries of what organoids can reveal about cardiac biology and therapeutic potential.

In summary, the self-assembled chamber-like cardiac organoids developed by Zou et al. represent an extraordinary technological and conceptual advance. By recapitulating the form and function of human cardiac chambers in vitro, they provide a powerful tool for unraveling the complexities of heart development and disease, enabling safer drug discovery, and opening new horizons for regenerative therapies. This landmark study heralds a new era in cardiovascular research where the heart’s mysteries can be explored with unprecedented clarity, precision, and relevance.

Subject of Research: Cardiac development, cardiac organoids, cardiotoxicity assessment, tissue engineering.

Article Title: Self-assembled chamber-like cardiac organoids for modeling cardiac chamber formation and cardiotoxicity assessment.

Article References:
Zou, X., Wang, F., Zheng, H. et al. Self-assembled chamber-like cardiac organoids for modeling cardiac chamber formation and cardiotoxicity assessment. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73822-6

Image Credits: AI Generated